Novavax shares rose in separate reported sessions as investors weighed updated Nuvaxovid approvals, renewed Sanofi royalties, higher 2026 revenue guidance and speculation about Matrix-M. Retail traders discussed an unconfirmed claim that the proprietary adjuvant has mostly mild-to-moderate, self-limiting side effects and potential oncology applications, but Novavax has not disclosed supporting safety data or announced a related deal. The company said partners are conducting experiments across more than 30 infectious-disease and oncology areas. Partners received August 28 approvals for an XFG-adapted Nuvaxovid formulation, while the FDA separately authorized Novavax’s updated protein-based 2026–2027 vaccine in late August. Novavax reported second-quarter revenue of $56.7 million, including a 76% year-over-year increase in product sales tied to Matrix-M demand, and raised its 2026 adjusted total revenue framework to $235 million-$275 million. Earlier reporting cited second-quarter revenue of $415 million, reflecting a broader figure that included strategic milestone payments. Sanofi’s high-teens royalty structure on global Nuvaxovid net sales resumes for 2026 and 2027, supporting Novavax’s partner-led, lower-cost model.